Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly insulin icodec vs once-daily insulin glargine U100 in adults with type 2 diabetes
jRCT2031240028Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2024
- Modality
- Peptides
01
Overview
Randomised trial of insulin icodec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Apr 2024; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031240028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240028.